Novartis Reports Rare Tumor Cases Following Zolgensma Treatment in Children
Swiss pharmaceutical company Novartis is facing increased regulatory scrutiny after disclosing nine reports of tumors in children who previously received its gene therapy Zolgensma, including two cases in which investigators found evidence connecting the tumors to the treatment.
The disclosure, made public in November 2026, has prompted renewed attention to the long-term safety of one of the world’s most expensive genetic medicines. The US Food and Drug Administration (FDA) announced on November 6 that it was investigating a potentially serious risk of tumor formation, including cancer, associated with the treatment.
The development is significant for families affected by spinal muscular atrophy (SMA), a rare inherited condition that causes progressive muscle weakness. Zolgensma has been used to treat thousands of children worldwide, offering a treatment that addresses the genetic cause of the disease rather than only managing its symptoms.
Nine reports bring renewed attention to gene therapy safety
Novartis said it had received nine reports of tumors in patients previously treated with Zolgensma since the medicine was first approved in 2019.
The company reported that two of these cases showed evidence of genetic material from the viral delivery system becoming integrated into the patients’ DNA. Both affected patients underwent treatment for their tumors and remain under medical observation, according to the company’s statement shared with SMA Europe on November 5.
More than 6,000 patients have received Zolgensma through clinical trials, managed access programs and commercial treatment, according to Novartis.
The nine reports do not mean that all nine tumors were caused by the medicine. Establishing a direct relationship requires detailed medical and molecular investigations.
Information published by Muscular Dystrophy UK on November 6 provided additional detail. Pathology testing had been completed on three of the nine reported tumors at that point. Two showed a specific relationship to Zolgensma, while the third appeared unrelated to the treatment.
The remaining cases had not yet been fully characterized in the publicly available information.
FDA launches investigation into possible cancer mechanism
The US regulator’s announcement on November 6 raised the significance of the findings beyond routine adverse-event reporting.
The FDA identified three cases involving tumors associated with GLI1, a gene linked to abnormal cell growth and cancer development when overexpressed or activated inappropriately.
In two cases, molecular testing demonstrated that DNA from the Zolgensma delivery vector had integrated into the patients’ genetic material. Investigators found that the inserted genetic material was positioned upstream of or within the GLI1 gene.
The mechanism behind GLI1 overexpression in the third case remains under investigation.
The FDA also identified reported tumors affecting the central and peripheral nervous systems, spinal and paraspinal regions, and kidneys.
The findings are important because they provide evidence of a possible biological mechanism through which a gene therapy could contribute to tumor development. However, the available evidence does not establish that every tumor reported after treatment was caused by Zolgensma.
The agency is assessing whether existing safety information and long-term monitoring arrangements are sufficient to address the newly identified risks. It is also considering whether additional regulatory action is appropriate.
How Zolgensma works
Zolgensma, whose active ingredient is onasemnogene abeparvovec, is designed to treat spinal muscular atrophy caused by changes affecting the survival motor neuron 1 (SMN1) gene.
People with this condition do not produce sufficient functional survival motor neuron protein, which is essential for maintaining motor neurons. These nerve cells control voluntary muscle movement.
Without adequate protein, motor neurons progressively deteriorate, resulting in muscle weakness and potentially life-threatening complications.
The treatment uses an engineered adeno-associated virus (AAV) vector to deliver a functional copy of the SMN1 gene into cells.
Unlike conventional medicines that generally require repeated administration, Zolgensma is given as a single intravenous infusion. In the United States, it is approved for pediatric patients younger than two years with the relevant genetic form of SMA.
Its approach has made the treatment an important development in the management of a serious childhood disease.
However, introducing genetic material into cells also creates scientific questions about how the delivered DNA behaves over time. The possibility that AAV vector DNA could integrate into a patient’s genome has been recognized in the medicine’s safety information.
Long-term monitoring becomes a central issue
One of the most important questions arising from the disclosure concerns how patients should be monitored years after receiving treatment.
Gene therapies can produce long-lasting biological effects. Consequently, safety assessments may need to continue well beyond the initial treatment period.
Novartis says the potential risk of tumor formation associated with vector DNA integration is already included in Zolgensma’s prescribing information. The company also says it has notified health authorities about the reported cases and is cooperating with regulators.
The FDA confirmed that Novartis is conducting long-term safety follow-up studies. However, the agency is now evaluating whether the existing prescribing information and monitoring arrangements adequately address the newly identified evidence.
In England, the National Multidisciplinary Team responsible for coordinating access to Zolgensma said on November 6 that its review of the available information was continuing.
Its published guidance stated that no changes to routine care or follow-up, including additional scans or tests, were recommended at that time in the UK context.
The recommendation is specific to the information and clinical arrangements available to that team. It should not automatically be interpreted as medical guidance for patients in other countries.
Families whose children have received Zolgensma are encouraged to discuss individual concerns with their treating medical teams.
Another Novartis treatment also comes under scrutiny
The FDA’s investigation extends beyond Zolgensma to include another Novartis gene therapy, Itvisma.
Although the two treatments are administered differently, they contain the same AAV vector and genetic construct.
Zolgensma is delivered through an intravenous infusion and is approved in the United States for eligible children younger than two years.
Itvisma, by contrast, is administered through an injection into the spinal canal and is approved for adults and pediatric patients aged two years and older with SMA.
The FDA said the potential risk of neoplasia, including malignancy, is relevant to both products because they share the same vector and construct.
However, the agency emphasized an important distinction: no cases of neoplasia following Itvisma administration had been reported as of its November 6 announcement.
The regulator is also monitoring similar AAV-based gene therapy programs, indicating that the investigation could have implications beyond a single pharmaceutical product.
Despite the identified safety concerns, the FDA stated that the overall benefits of Zolgensma and Itvisma continue to outweigh their potential risks for their approved uses.
Patient organizations seek clearer information
The disclosure has also placed pressure on pharmaceutical companies and regulators to communicate safety information clearly to families.
SMA Europe said the emerging reports were causing concern among people affected by the disease and their relatives. The organization called on Novartis to explain what was known, what remained uncertain and whether additional monitoring might become necessary.
The organization also said it had raised concerns about the need for timely public communication.
The Muscular Dystrophy Association in the United States similarly emphasized the importance of transparent, science-based information. Its November 5 statement noted that important details about the tumors, their timing and potential future monitoring requirements remained unavailable.
These responses reflect a difficult challenge in rare-disease medicine. Families making treatment decisions need reliable information about both the potential benefits of a therapy and its risks, including those that may only become apparent after years of follow-up.
For children already treated, uncertainty about a possible long-term complication can be particularly difficult for parents and caregivers.
At the same time, the reported cases need to be interpreted against the number of patients treated and the evidence available from individual investigations. Nine tumor reports among more than 6,000 treated patients should not be treated as nine confirmed treatment-related cancers.
What happens next?
The FDA’s investigation is now a critical part of determining whether the existing safeguards surrounding Zolgensma remain adequate.
Further molecular analysis, clinical information and long-term patient follow-up could help establish how the reported tumors developed and whether additional precautions are justified.
The regulator has not announced a withdrawal of Zolgensma or concluded that its approved uses should be discontinued. Its November 6 statement instead confirmed that the agency is examining the new evidence and considering whether changes to the product’s regulatory requirements are necessary.
For Novartis, the immediate challenge involves addressing the safety concerns while providing accurate information to healthcare professionals, patients and their families.
For the wider gene therapy industry, the findings underline the importance of evaluating treatments over extended periods, particularly when their mechanisms involve introducing genetic material into human cells.
Zolgensma remains an important treatment option for children with spinal muscular atrophy. But the latest reports demonstrate why the long-term safety of advanced genetic medicines must continue to receive close scientific and regulatory attention.
The next phase of the investigation will depend on evidence from tumor analyses, patient follow-up and assessments by health authorities. Until those findings become available, the distinction between reported tumors, confirmed treatment-related cases and unresolved investigations remains essential to understanding the risks.
